Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioCryst Pharmaceuticals, Inc.    BCRX

Delayed Quote. Delayed  - 07/29 10:00:00 pm
3.62 USD   +4.62%
07/21 BioCryst to Announce Second Quarter 2016 Financial Results August..
07/06 BIOCRYST PHARMA : Receives Additional NIAID Funding to Advance Devel..
07/06 BRIEF : BioCryst Pharmaceuticals lands $5.5 million in federal fundi..
News SummaryMost relevantAll newsSector news 

BioCryst Pharmaceuticals, Inc. : Commentary & Reports For: (NASDAQ: BCRX), (NYSE: GST)

share with twitter share with LinkedIn share with facebook
share via e-mail
04/24/2013 | 07:45pm CEST

New York (April 24th, 2013) - BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) traded in the range of $1.75 and $1.97 during its latest trading session. The stock recorded the volume of 1.986 million shares. Currently, it is at $1.93, up 7.23 from its previous close. Its average daily trading volume stands at 1.085 million shares. Its MACD chart shows bullish trend and the stock is trading above its long term moving average price of $1.92. The company?s current market capitalization stands at $98.29 million.

BioCryst Pharmaceuticals stock is up 37.86 percent in the year 2013 so far while it lost 51.51 percent of its value in the past 52 weeks.

Find out if BCRX could maintain the momentum by getting the complete trend analysis report here:


Gastor Exploration Ltd. (NYSE: GST) stock is at $2.74, up 7.45 percent from its previous close of $2.55. The stock is up after the news of the company?s decision to sell its East Texas assets. Gastor Exploration shows bullish trend as it made the upward move with trading volume of 351,132 shares, in contrast to the average daily trading volume of 712,310 shares. Its bullish trend is further confirmed by its MACD chart and the stock is also trading above its 20 days SMA of $2.72.

Gastor Exploration stock is highly volatile with its beta at 1.57. The company?s market capitalization is at $186.18 million.

Get more news and reports on how to successfully trade GST here:



MonsterTradingAlerts.com issues momentum alerts on stocks that can provide gains to day traders. MonsterTradingAlerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. MonsterTradingAlerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals MonsterTradingAlerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the MonsterTradingAlerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.MonsterTradingAlerts.com

Disclosure: MonsterTradingAlerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit MonsterTradingAlerts.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.monstertradingalerts.com/disclaimer/

Contact Info:
Alexander K. Neumann
Monster Trading Alerts

© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
07/21 BioCryst to Announce Second Quarter 2016 Financial Results August 4
07/06 BIOCRYST PHARMACEUTICALS : Receives Additional NIAID Funding to Advance Developm..
07/06 BRIEF : BioCryst Pharmaceuticals lands $5.5 million in federal funding
07/06 BIOCRYST PHARMACEUTICALS : receives $5.5M in NIAID funding for potential Ebola t..
07/05 BIOCRYST PHARMACEUTICALS INC : Entry into a Material Definitive Agreement, Other..
07/05 BioCryst Receives Additional NIAID Funding to Advance Development of BCX4430 ..
05/27 BIOCRYST PHARMACEUTICALS : to Present at Two Upcoming Investor Conferences
05/26 BioCryst to Present at Two Upcoming Investor Conferences
05/25 BIOCRYST PHARMACEUTICALS INC : Change in Directors or Principal Officers, Submis..
05/06 BIOCRYST PHARMACEUTICALS : shares dip on sluggish Q1 earnings
More news
Sector news : Bio Therapeutic Drugs
07/29DJMerck Revenue Rises on Cancer, Hepatitis Treatments
07/29DJMERCK : Revenue Rises on Cancer, Hepatitis Treatments
07/29DJSanofi Profit Down as Diabetes Drug Sales Slip
07/28DJCELGENE : Lifts Guidance as Revlimid Sales Rise -- Update
07/28DJU.S. HOT STOCKS : Hot Stocks to Watch
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
07/29 Local cases of Zika transmission reported in Florida
07/22 WALL STREET BREAKFAST : Markets Get First Glimpse Of Post-Brexit Data
07/22 More Zika worries
07/20 WALL STREET BREAKFAST : Big Tumult At Fox News
07/20 Florida may have first local case of Zika in U.S.
Financials ($)
Sales 2016 19,1 M
EBIT 2016 -73,3 M
Net income 2016 -75,4 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 13,9x
Capi. / Sales 2017 8,54x
Capitalization 267 M
More Financials
Duration : Period :
BioCryst Pharmaceuticals,  Technical Analysis Chart | BCRX | US09058V1035 | 4-Traders
Full-screen chart
Technical analysis trends BIOCRYST PHARMACE...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 9
Average target price 6,75 $
Spread / Average Target 86%
Consensus details
EPS Revisions
More Estimates Revisions
Jon P. Stonehouse President, Chief Executive Officer & Director
George B. Abercrombie Chairman
Robert Bennett Vice President-Investor Relations & Operations
Thomas R. Staab Chief Financial Officer, Treasurer, CAO & SVP
William P. Sheridan Chief Medical Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN, INC.5.98%129 232
GILEAD SCIENCES, INC.-21.46%105 840
More Results